Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
� � ����������Vol. 36, pp. 71�82, 2008
����������� ������
���
���
���
�
���
��
���
��
��� :� 20 4 � 7 ��
�������� ����� ����� �������
��
� 2 !�"#$%!�&'(����)���#*�+,-./0� 1 ) cDNA �12��314506���7��89�:+);<,=>���?@+�/>��!A�BCDE FGH )I��! �J�?@!�&'(K�LM> �����CD0� �N#6��OP+�Q4RS O#T>I���U+ V0!"!WXCD0��+ Y!I���U'( �=. ���#ZCY![$+ \��) ]M'(!����!^_�`�a#%&4#T./\F!,bcM0� 7d'ef�D0/)'egh(i4D0 ���#Z) j,�k���lBm) V#cS���n+��,V0F!CD0 �� 1�� ���n$%!*o)p\ +,�# ���CD0 ErbB2�HER2 ����nCD0],��qLM>!) 20rCD0� ]M4-=. �������������s.!'t+u0������v�n!*o)w\ +,�#x��8CD0 RING 89�v��������v�nCD0],�c'T>!) 1999C1� j,�k!������v�n)Y!y4�qLM./0� z/�4)���n5E)0'4�\!{0!������v�n�1dV0],'( �����B|}�z/J�4&>V2~)3P4�N' �4C �� ]!s.+��,=>����#Z�K�LM./0 �� 1�� �����_�CD0�������5�Z!�:��
�� �bortezomib: Velcade PS-341� ���U���467#�&+8<>],'( �y �������������s.+��4=>9!���Z�'e!�4:�=.\0],��;LM./0��> �<!#ZCFY!�&�74�������������s.��\�cT./0],�c'E ]!s.!�=#I��J�+>?V0],)���?!G�CF�4,#T./0� @�C)�������������s.!�� �������5�Z!7�4��6�(!�A BCD0C��4�D=>��4 /.? V0�
� �������������
�������������s.) ¡4 4 !m) V#cS�����¢UBm) �E1� �����£Xm) �E2� ������v�n �E3� ¤5¥ 26S �������45T.¦�LM.¤E ]M(!§�45T.��_�¨2© ��©�!�ª�«�4�����+1�¬��a£XL02�, 3� �� 1�� �����) 1978 4 Ciechanover, Hershko 45T.�qLM> 76 ��®l8kDa !3P4¯L#_�¨2©CD04����_�¨2©4£X=>�����!�ª�«�4L(4°!������£X= ]!±EE=45EC">²������B_�¨2©))F\26S�������45T.8³LM ?LM05��7�� GH �5E#0 E1 ¤5¥ E2 ,O#EE3 )H´! �450HX�CD0],��\Y!I4�©�����OU+µJV0¶��·���¸�M./0� z/�!¦K¤5¥¹º!LB4��������� �»��C¼�� M»�
71
71
���������� �������� ������������ !"� �����#$%&'"()*+��,-� ./01()23�,-456�7��26S 89:;<=>#?@����AB'CD�E� 20S 89:;<=>/F�GH�I�J4K
LE���MNOPQRS� 19S 89:;<=>�PA700� TUVW�� �� 1�� 19S 89:;<=># Lys-48 XPYZ[���� \�]^6� _��`��aKH4�bc6� `�#F�dd 20S89:;<=>4e1�������� _�f4�gh/gijk��� lmno>��p���7
� 1 �9q �r=s�it89:;<=>��Nu'/6.vwx
� 1 ���� �89:;<=>yz
{|}~ ����72
72
���������� ��������������������� ! 7"�������� Lys #$�%& Lys-48 '()*�+),-.�����/01�2����� 3�� ������0 �������4 5678�96�:�;�� �reviewed in Pickart et al., 2001�� <=����� >��?�@�AB �endocytosis� C>�����D0� Lys-63 '(),-.�����/ en-docytosis� DNAE�� IKK �I kappa B kinase� F��� G1H.IJ��EK���4)*L*L� �� 2��MNOP 44)*Q0GL*� 500����R;�SN��0T)*� �����.U�R 1000 VW�S)� �����EK � ��.�X�4��� ��L Y!VW0� >���:�0Z[\*L� 4;�]�P�� ^S_�0GL*96�`a; �b�'��4),c�d�e��f�0@�gh�L��
��������
�������������b�'��4),�i���jk0�lm�n!,� ��������o�I��Jpq���8�� �r���s��t�),9��uvwxy�� 1�30GL*I��Jpq�z{;�|}!9�� �~.�e���FDA� � 2003 I��Jpq'9��uvw��i4)*��),� I��Jpq � Y�C!��I��X; 20S ���������<�.��F�"���������0+eN� 401�� ��
�0�������'�oN�10�� 9��uvw0TN�I��Jpq��#�� � $�8�#�d01\*2,}n!� 4;%�n!*L�;11��L�!2�&�82� 8L� 'y} ���������i; 26S �������'�oN� 401�� >��0��n!8L-.�����'(�n�� ������.����')��+{4)*���*���8�.�������;�+N�^�0,-)*L�� ����.�8�����;�+N� 401�� DNA��E�0./8�����������;�P868�12�, 13� �� 3��;h>�8 �0¡�>�¢£�2DNA��;¤120� �>�� �-���;34n!� 4;�]n!�� ¥,� DNA ��'��N��i4�5��¦§z{;�|}!� �6¨� unpub-lished data��I��Jpq��l©ª � «¬x4 �phaseII trial on cutaneous T-cell lymphoma by Jonsson
Comprehensive Cancer Center, NCT00182637�«¬xV®�¯�w7 �phase II trials on advancedbronchiolo-aveolar carcinoma �BAC� or adenocar-cinoma by the Irish Clinical Oncology Research
Group NCT00513877� �G 8[!*L�� ^S�4 °� ±²;h0GL* 8}³8z{ �|}!*L8L� )³)� !}�©ª third line
V´���4)*µ[!*L� 4;96� 9;h0GL* :; 1 V�;�]n!�¶|*�·;¯L¸µ�9;h 12<0T)*�I��Jpq¹i=>�%�;���B���14�� º�<��»�
� 2 �����EK�¼?4:�
�������������b�4;h�� 73
73
a b c d
e f g h
li j k
��� HER2 ��������� ������������������������������������� !"#$�%&'()�*+�,��-./�01��2�3��� �� 1�� 45%&'()�*6���789:;<=> A�NPI-0052� �<?�@:#$�A1�BC��D�%&'()�*,EFGH�6I�15��17�� J;")KL@$ �epoxomicin� �J;MKL@$ epone-mycin�� J;"@N/$OPQ1RSTU��D� VW�����18�, 19�� J;")KL@$��XYZ[\]���%&'()�*6�� 20S%&'()�*�"^/8%@$ _`�EFGH�a�I�� b�J;")KL@$�� c:d�e �"^/8%@$ _`����a�I�20��22��J;")KL@$�fg�B���� PR-171�h�� in vitro �ij]kl]mnop��qr,
6I���stuQ123��
��������� ��������������
vwxy^$z{%��@|}y�~� ���,���� ����qr����i��� �������J:/&-$z{%�� a
�ERa� �� !"#$�%&'()�*+����i��uQ�� 01�i� �����Q�%&'()�*����p�,�3I�����Q�� 0�0� ����%&'()�*����ERa @|}y,6I�� !"#$�%&'()�*+���� ERa ��������Z 2��+�� I���8�$>���H���H���XI� �� 4��8�$>���H����� ��/@ .?¡m¢ Hsp70� Hsp90 �£fC���1 U-box !"
� 3 %&'()�*������ DNA ¤¥_`� !"#$ foci ¦g���HeLa p��c$%/'@$�BC CPT-11 ,§��� DNA2 �¨©ª_`�8$«�01 H2AX �gH2
AX� foci ¬�� �e, i�� �� foci �� u�� DNA ®¯°�±²� !"#$¨��� foci ¬guQ� �f��� %&'()�*��� MG132 ���i !"#$p�¢�/<.%uQ�� DNA ¤¥_`� !"#$ foci �¬guQ���� ��j�� DAPI: v³´
µ¶·¸ ¹º»¼74
74
�������� CHIP � �� ������������������ ERa ����� ��� !"� "�#$�%&�' ERa %(�����%��24�, 25�� ����)*+� !'� ,-.��/012������34��5#�� �% !' ERa%67893:;��� <%=>?��@ABCD�E�F��� MG132�G�H�/I�� ERa'JKL" ERa346789'�F"�?MH�/26�� ERaNO9@AP�Q� �ER responsive element; ERE� %67893' ERE R3 ERa%ST��UVWX�Y��?:���27�, 28� �� 4�� �%Z� ERE R% ERa %[\3012���@ABCD�E&�]���� @ABCD�E�^_"?ERa�`Ca�b�Q��012������cTd ERE R3e���f�� 2g�hi% ERa
%@AP�Q�j%ST^_H�� ��3k#���lm('� 1� 012�������� E6AP29�, 30�� MDM231�� EFP32�� 2� 20S @ABCD�E%no0pqr LMP233� ? 19S @ABCD�E%no0pqr Rpt6�TRIP1�SUG127�� 3�LMP2? ERa �st"�BAu�vw@Q�`Ca�b�Q� SRC32�� E6AP ? ERa �st"�BAu�vw@Q�`Ca�b�Q� AIB134�
�� AIB1 'xyI�3z{|��}W� f/� AIB1�z{|H~/���'� ����xy}4����������xy���H�� �����%�-%�%� ERa% !3���}4�"35�� }�����?3 ERa C�Q�p�r% �b�r��r �ful-vestrant, ICI182780� ? RU58668 ' ERa % !���"36�� �b�r��r' ERa �R��/ERE R%nua�����H~� �%012������34 !���H~� �� AIB1 'C�Q�p�r�'�-C�p�r��'��rA��)*+3 ERa% !���" �� 4�� �/�� AIB1 %�F'��rA��34�� H� ERa% !��F�� ERa3467��F"� fulvestrant¡ GW5638 � H� ERa
% !'^_���34�� ���%S¢��� �b�r��r? AIB1 ^_�%£�34 ER�9xy%¤�3}¥¦§¨¢©ªH�� R«��'012���@ABCD�E&�3����¬�%?��®u�H������ 012���@ABCD�E&��¯°"��?��±²���� �%³´��µ?� 012���@ABCD�E&�34 ERa !&� �� 4�'¶�P�)*9y%¤�%·+?�¸²9�¹��
� 4 012���@ABCD�E&�?��rA��º»¼�
012���@ABCD�E&�?y¤� 75
75
���
HER2, EGFR ����������� ��
��������� ������������������� ���� �Growth Fac-tor, GF� ����������� �� ������ �GFR� ��� EGFR �epidermalgrowth factor receptor, �� ErbB1�HER1� HER2 �ErbB2�Neu� � �!�"���"#$��%��&�'�(��� ����)�*����37��39�� GFR �+,%#��$-./�01�����23 ERa ���45�67� � �7� ��2����EGFR 45�6��� EGF 7� � 2 ��8�� 9� 2��8��:����6';��#$��%��&�<�8=>� ?��@ABC����� Grb2 D Shc �4�E8=F� <�8G��� 5A�� 9�H� EGFR ��I�#$��JK�LM4�E8 +,%#�45�&��� Cbl34�E8�40�� Cbl � EGFR N�OP Cbl �<�8QRST9G� U�OV EGFR Cbl ��:��W+,%#�8=F� @�6/�0�XYF� 99�/�-Z��=F��23�[ \��=F�� 9�] ^5-Z_AZ�6(`Cab�cdQ��:���3� efgF���� c�4�E8=F� HER2 Cbl �OP��[ Cbl 7� �2������41�� HER2 �h �*G� HER2�EGFR �i-$ 2 ���!j� EGFR �Cbl 7� ��2Q"#�� U�<�Q�)=>�41��44� �� 5B�� k3�l�9 �mnopqr_��� HER2 � Tyr1112 �4�E8 Cbl �OPQRST9�� HER2 Q�2�$%G� �� 5B��c�� 45�6�7� � HER2 ��2 �
ERa ��� Hsp70� Hsp90 OP�� CHIP ��:�stF�45��48�� ���:�� 9�a&Q'(G�)u � mnpor_ �*��v��w��xVQy+G�9 ��S�� w��u�,-�z.��{ Hsp90 �OPG�|�}�r;���geldanamycin� � ~ ��z.���� ���CHIP 7� � HER2 ��2 #$��"#)��� CI-1033 ��:�'(=F��� CI-1033 |�}�r;�� /0���Q1� �"#G�49��
BRCA1� basal-like ���
.$r��&2�uQ34 ����567��� mnopqr_ �trastuzumab� �%8�����6 �� 10 9�:;Q �� �������<���� HER2 <������=> �?��� U�OV �� ER ��� PR ���HER2 ���� (s�@[A����� �t��m4�^5-Z_����C$�q.`=F���� m4�^5-Z_��� cDNA r;C$.�;�B����C��*$A�;4����{�D=F� 5���_�;� G�t� lumi-nal A� luminal B� normal breast-like� HER2 h �*� basal-like ��� basal-like ������cEG�9 �t�:�� 9�"��� � basal��FG���r�������;m�n#� 5�6�14� 17� ,'�#�Q�*����50��52��� ERa�PR� HER2 Q�*������ �������H15������ 9��_�; A����������{�I�QJ��9 �g� U�A���K � ���L��A���K�MS[��G��F��NOQ����� basal-like �����C��*$A�;�� BRCA1 :���� P���� ¡¢G�9 �g� BRCA1 �C�:�£¤� BRCA11��a&QL���� basal-like ���QS�G¥� ��efgF���� ¦H��R����� FG��N� � BRCA1 k�§p53�:�Q%8��r¨o �S�©>� basal-like ���Q!j�� BRCA1 DNA TUªVWXY�Z[��{� BRCA1 �o��6��S��� DNA \]�^G�«_��`a�b(G�����:� BRCA1 basal-like����k¬�w��u«_�Q2BG�F�St��������BRCA1 � ��cy�k¬�#B`C;�mab� DNA XYab� 34�#®ab�¯�k�� p53 3�°_deI �fgChab�±²i�³jG�deI� ��k����� DNA TUªVWXY�k¬� BRCA1 �l´ 1�mµfXYQnok9�� BRCA2 D Rad51 �¯�@ABC��Q\]I³�$%G�'¶Z@������� ·[��� 9�1��'�¸q0 pq �2a=F�� G�t�� rstDm¹;/'n�&2�u�¯���DNATUªVW�!j� � �º ATM ��:�\]I³�»om� H2AX �4
u?v¼ wxyz76
76
� 5 ����������� �� EGFR�HER2����
����������� ������ 77
77
����� �� 3e�� ����� �� ������������ RNF8 �������� !"�� Lys-63 #$%�&������'�()*�53��55� �� 3f��� ��&������'� RAP80 +,-./ BRCA1 ��0*��56��58�� BRCA1 1BARD1 ��2� RING2 �3%����������+()���59��62�� ��4��56� BRCA1- BARD1 �7819�*�/: :� ;<=1�BRCA1- BARD1 �78�>?�./ NPM1 +@A./5�63�� ��4��5:/2 NPM1 ���������B/CDE����FG��H�IJ� BRCA2 � Rad51 ���K@LMN�O./P�./:�2��QN/:��R�STU�V�WDXYZ�[\]^1��DNA _�'`abc�56� !"��������+�d����e=DNA_�'`a+fg��"&hZij��\]^���Y�"jkhC��l�^mn�W"Xo�� DNA CD!��n����o!Wj��mnpqWj���Krst+2uvwx���� �y� BRCA1 4��zw��d*�/:� basal-like {�|�1}�L~��T/DNAbc���\]*����e=� ��|^�./st�����������
����
��� ���5���(�|�56�WDXYZ�[\]��������+���������� ���y�������*��vwx���� WDXYZ�[1�|���ee�=��/������/�� zw�¡�B/:��2ee�=�� ¢�\]^�£�¤¥�¦§���¨x©ª�����vw��BU��1«¬�T������ ��� ��« I®¯ §�+ �����������+° ��������� *=�¦§��± :��|^�²¨2��*������������WDXYZ�[4�+° �.U³��´�.U:�
���
1� Ohta. T., Michel. J. J , Schottelius, A. J, andXiong, Y.: ROC1, a homolog of APC11, repre-
sents a family of cullin partners with an associ-
ated ubiquitin ligase activity. Mol. Cell 1999;
3: 535�541.
2� Hershko A and Ciechanover A. The ubiquitinsystem. Annu Rev Biochem 1998; 67: 425-
479.
3� Pickart CM and Eddins MJ. Ubiquitin: struc-tures, functions, mechanisms. Biochim Bio-
phys Acta 2004; 1695: 55-72.
4� Ciehanover A, Hod Y and Hershko A: A heat-stable polypeptide component of an ATP-
dependent proteolytic system from reticulo-
cytes. Biochem. Biophys. Res. Commun 1978;
81: 1100�1105.5� Pickart CM. Back to the future with ubiquitin.Cell 2004; 116: 190.
6� Mukhopadhyay D and Riezman H. Protea-some-independent functions of ubiquitin in en-
docytosis and signaling. Science 2007; 315:
201�205.7� Ohta T and Fukuda M. Ubiquitin and breastcancer. Oncogene 2004; 23: 2079�2088.
8� Hideshima T, Richardson P, Chauhan D,Palombella VJ, Elliott PJ, Adams J and Ander-
son KC. The proteasome inhibitor PS-341
inhibits growth, induces apoptosis, and over-
comes drug resistance in human multiple mye-
loma cells. Cancer Res 2001; 61: 3071�3076.9� Richardson PG, Barlogie B, Berenson J, Sing-hal S, Jagannath S, Irwin D, Rajkumar SV,
Srkalovic G, Alsina M, Alexanian R, Siegel D,
Orlowski RZ, Kuter D, Limentani SA, Lee S,
Hideshima T, Esseltine DL, Kau#man M, Ad-
ams J, Schenkein DP and Anderson KC. A
phase 2 study of bortezomib in relapsed, refrac-
tory myeloma. N Engl J Med 2003; 348:
2609�2617.10� Adams J. The proteasome: structure, function,
and role in the cell. Cancer Treat Rev 2003; 29
Suppll 1: 3-9.
11� Hideshima T, Chauhan D, Richardson P, Mit-siades C, Mitsiades N, Hayashi T, Munshi N,
Dang L, Castro A, Palombella V, Adams J and
Anderson KC. NF-kappa B as a therapeutic
target in multiple myeloma. J Biol Chem 2002;
277: 16639�16647.12� Dantuma NP, Groothuis TA, Salomons FA
µ¶·¸ ¹º»¼78
78
and Neefjes J. A dynamic ubiquitin equilib-
rium couples proteasomal activity to chroma-
tin remodeling. J Cell Biol 2006; 173: 19-26.
13� Mailand N, Bekker-Jensen S, Faustrup H, Me-lander F, Bartek J, Lukas C and Lukas J.
RNF8 ubiquitylates histones at DNA double-
strand breaks and promotes assembly of repair
proteins. Cell 2007; 131: 887-900.
14� Yang CH, Gonzalez-Angulo AM, Reuben JM,Booser DJ, Pusztai L, Krishnamurthy S, Es-
seltine D, Stec J, Broglio KR, Islam R, Horto-
bagyi GN and Cristofanilli M. Bortezomib
�VELCADE� in metastatic breast cancer: phar-macodynamics, biological e#ects, and predic-
tion of clinical benefits. Ann Oncol 2006; 17:
813�817.15� Feling RH, Buchanan GO, Mincer TJ,
Kau#man CA, Jensen PR and Fenical W. Sa-
linosporamide A: a highly cytotoxic protea-
some inhibitor from a novel microbial source,
a marine bacterium of the new genus salino-
spora. Angew Chem Int Ed Engl 2003; 42:
355-357.
16� Chauhan D, Catley L, Li G, Podar K, Hide-shima T, Velankar M, Mitsiades C, Mitsiades
N, Yasui H, Letai A, Ovaa H, Berkers C,
Nicholson B, Chao TH, Neuteboom ST, Rich-
ardson P, Palladino MA, Anderson KC. A
novel orally active proteasome inhibitor in-
duces apoptosis in multiple myeloma cells with
mechanisms distinct from Bortezomib. Cancer
Cell 2005; 8: 407-419.
17� Joazeiro CA, Anderson KC and Hunter T.Proteasome inhibitor drugs on the rise. Cancer
Res 2006; 66: 7840-7842.
18� Hanada M, Sugawara K, Kaneta K, Toda S,Nishiyama Y, Tomita K, Yamamoto H, Kon-
ishi M and Oki T. Epoxomicin, a new antitu-
mor agent of microbial origin. J Antibiot �To-kyo� 1992; 45: 1746-1752.
19� Sugawara K, Hatori M, Nishiyama Y, TomitaK, Kamei H, Konishi M and Oki T. Epone-
mycin, a new antibiotic active against B 16
melanoma. I. Production, isolation, structure
and biological activity. J Antibiot �Tokyo�1990; 43: 8-18.
20� Sin N, KimKB, Elofsson M, Meng L, Auth H,Kwok BH and Crews CM. Total synthesis of
the potent proteasome inhibitor epoxomicin: a
useful tool for understanding proteasome biol-
ogy. Bioorg Med Chem Lett 1999; 9: 2283-
2288.
21� Meng L, Kwok BH, Sin N and Crews CM.Eponemycin exerts its antitumor e#ect through
the inhibition of proteasome function. Cancer
Res 1999; 59: 2798-2801.
22� Meng L, Mohan R, Kwok BH, Elofsson M,Sin N and Crews CM. Epoxomicin, a potent
and selective proteasome inhibitor, exhibits in
vivo antiinflammatory activity. Proc Natl
Acad Sci USA 1999; 96: 10403�10408.23� Stapnes C, Doskeland AP, Hatfield K, ErsvaerE, Ryningen A, Lorens JB, Gjertsen BT, Brus-
erud O and Br J Haematol. The proteasome
inhibitors bortezomib and PR-171 have anti-
proliferative and proapoptotic e#ects on pri-
mary human acute myeloid leukaemia cells
2007; 136: 814�828.24� Tateishi Y, Kawabe Y, Chiba T, Murata S,Ichikawa K, Murayama A, Tanaka K, Baba T,
Kato S and Yanagisawa J. Ligand-dependent
switching of ubiquitin-proteasome pathways
for estrogen receptor. EMBO J 2004; 23:
4813�4823.25� Fan M, Park A and Nephew KP. CHIP �car-boxyl terminus of Hsc70-interacting protein�promotes basal and geldanamycin-induced
degradation of estrogen receptor-alpha. Mol
Endocrinol 2005; 19: 2901�2914.26� Lonard DM, Nawaz Z, Smith CL and O[Mal-
ley BW. The 26S proteasome is required for
estrogen receptor-alpha and coactivator turn-
over and for e$cient estrogen receptor-alpha
transactivation. Mol Cell 2000; 5: 939�948.27� Reid G, Hubner MR, Metivier R, Brand H,
Denger S, Manu D, Beaudouin J, Ellenberg J
and Gannon F. Cyclic, proteasome-mediated
turnover of unliganded and liganded ERalpha
����������� ������ 79
79
on responsive promoters is an integral feature
of estrogen signaling. Mol Cell 2003; 11: 695-
707.
28� Zhang H, Sun L, Liang J, Yu W, Zhang Y,Wang Y, Chen Y, Li R, Sun X, Shang Y. The
catalytic subunit of the proteasome is engaged
in the entire process of estrogen receptor-
regulated transcription. EMBO J 2006; 25:
4223�4233.29� Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, Tsai MJ and O[Malley
BW. The Angelman syndrome-associated pro-
tein, E6-AP, is a coactivator for the nuclear
hormone receptor superfamily. Mol Cell Biol
1999; 19: 1182�1189.30� Li L, Li Z, Howley PM and Sacks DB. E6AP
and calmodulin reciprocally regulate estrogen
receptor stability. J Biol Chem 2006; 281:
1978�1985.31� Saji S, Okumura N, Eguchi H, Nakashima S,Suzuki A, Toi M, Nozawa Y, Saji S and Hay-
ashi S. MDM2 enhances the function of estro-
gen receptor alpha in human breast cancer
cells. Biochem Biophys Res Commun 2001;
281: 259�265.32� Nakajima A, Maruyama S, Bohgaki M, Miya-jima N, Tsukiyama T, Sakuragi N and Hatak-
eyama S. Ligand-dependent transcription of
estrogen receptor alpha is mediated by the
ubiquitin ligase EFP. Biochem Biophys Res
Commun 2007; 357: 245�251.33� Zhang H, Sun L, Liang J, Yu W, Zhang Y,
Wang Y, Chen Y, Li R, Sun X and Shang Y.
The catalytic subunit of the proteasome is en-
gaged in the entire process of estrogen receptor-
regulated transcription. EMBO J 2006; 25:
4223�4233.34� Shao W, Keeton EK, McDonnell DP andBrown M. Coactivator AIB1 links estrogen
receptor transcriptional activity and stability.
Proc Natl Acad Sci USA 2004; 101:
11599�11604.35� Wijayaratne AL and McDonnell DP. The hu-
man estrogen receptor-alpha is a ubiquitinated
protein whose stability is a#ected di#erentially
by agonists, antagonists, and selective estrogen
receptor modulators. J Biol Chem 2001; 276:
35684�35692.36� Marsaud V, Gougelet A, Maillard S and Re-noir JM. Various phosphorylation pathways,
depending on agonist and antagonist binding
to endogenous estrogen receptor alpha �ERal-pha�, di#erentially a#ect ERalpha extractabil-ity, proteasome-mediated stability, and tran-
scriptional activity in human breast cancer
cells. Mol Endocrinol 2003; 17: 2013�2027.37� Harari D and Yarden Y: Molecular mecha-nisms underlying ErbB2�HER2 action in breastcancer. Oncogene 2000; 19: 6102-6114.
38� Bhargava R, GeraldWL, Li AR, Pan Q, Lal P,Ladanyi M and Chen B. EGFR gene amplific-
ation in breast cancer: correlation with epider-
mal growth factor receptor mRNA and protein
expression and HER-2 status and absence of
EGFR-activating mutations. Mod Pathol
2005; 18: 1027�1033.39� Park K, Han S, Shin E, Kim HJ and Kim JY.
EGFR gene and protein expression in breast
cancers. Eur J Surg Oncol 2007; 33: 956�960.40� Olayioye MA, Neve RM, Lane HA Hynes NE.The ErbB signaling network: receptor hetero-
dimerization in development and cancer.
EMBO J 2000; 19: 3159�3167.41� Muthuswamy SK, Gilman M and Brugge JS:Controlled dimerization of ErbB receptors pro-
vides evidence for di#erential signaling by ho-
mo- and heterodimers. Mol Cell Biol 1999; 19:
6845-6857.
42� Graus-Porta D, Beerli RR, Daly JM and Hy-nes NE. ErbB-2, the preferred heterodimeriza-
tion partner of all ErbB receptors, is a mediator
of lateral signaling. EMBO J 1997; 16:
1647�1655.43� Levkowitz G, Waterman H, Zamir E, Kam Z,Oved S, Langdon WY, Beguinot L, Geiger B
and Yarden Y. c-Cbl�Sli-1 regulates endocyticsorting and ubiquitination of the epidermal
growth factor receptor. Genes Dev 1998; 12:
���� ����80
80
3663�3674.44� Lenferink AE, Pinkas-Kramarski R, van de
Poll ML, van Vugt MJ, Klapper LN, Tzahar
E, Waterman H, Sela M, van Zoelen EJ and
Yarden Y. Di#erential endocytic routing of
homo- and hetero-dimeric ErbB tyrosine ki-
nases confers signaling superiority to receptor
heterodimers. EMBO J 1998; 17: 3385�3397.45� Zhou P, Fernandes N, Dodge IL, Reddi AL,Rao N, Safran H, DiPetrillo TA, Wazer DE,
Band V and Band H. ErbB2 degradation me-
diated by the co-chaperone protein CHIP. J
Biol Chem 2003; 278: 13829�13837.46� Xu W, Marcu M, Yuan X, Mimnaugh E, Pat-terson C, Neckers L. Chaperone-dependent E3
ubiquitin ligase CHIP mediates a degradative
pathway for c-ErbB2�Neu. Proc Natl Acad SciUSA 2002; 99: 12847�12852.
47� Citri A, Alroy I, Lavi S, Rubin C, Xu W,Grammatikakis N, Patterson C, Neckers L,
Fry DW and Yarden Y. Drug-induced ubiqui-
tylation and degradation of ErbB receptor ty-
rosine kinases: implications for cancer therapy.
EMBO J 2002; 21: 2407�2417.48� Connell P, Ballinger CA, Jiang J, Wu Y,Thompson LJ, Hohfeld J and Patterson C.
The co-chaperone CHIP regulates protein tri-
age decisions mediated by heat-shock proteins.
Nat Cell Biol 2001; 3: 93-96.
49� Honrado E, Osorio A, Palacios J and BenitezJ. Pathology and gene expression of hereditary
breast tumors associated with BRCA1, BRCA2
and CHEK2 gene mutations. Oncogene 2006;
25: 5837�5845.50� Perou CM, Sorlie T, Eisen MB, van de Rijn M,Je#rey SS, Rees CA, Pollack JR, Ross DT,
Johnsen H, Akslen LA et al: Molecular por-
traits of human breast tumours. Nature 2000;
406: 747�752.51� Nielsen TO, Hsu FD, Jensen K, Cheang M,
Karaca G, Hu Z, Hernandez-Boussard T, Li-
vasy C, Cowan D, Dressler L et al: Immuno-
histochemical and clinical characterization of
the basal-like subtype of invasive breast carci-
noma. Clin Cancer Res 2004; 10: 5367�5374.52� Sorlie T, Tibshirani R, Parker J, Hastie T,Marron JS, Nobel A, Deng S, Johnsen H,
Pesich R, Geisler S et al: Repeated observation
of breast tumor subtypes in independent gene
expression data sets. Proc Natl Acad Sci USA
2003; 100: 8418�8423.53� Kolas NK, Chapman JR, Nakada S, Ylanko J,Chahwan R, Sweeney FD, Panier S, Mendez
M, Wildenhain J, Thomson TM, Pelletier L,
Jackson SP and Durocher D. Orchestration of
the DNA-damage response by the RNF8 ubiq-
uitin ligase. Science 2007; 318: 1637�1640.54� Huen MS, Grant R, Manke I, Minn K, Yu X,Ya#e MB and Chen J. RNF8 transduces the
DNA-damage signal via histone ubiquitylation
and checkpoint protein assembly. Cell 2007;
131: 901�914.55� Mailand N, Bekker-Jensen S, Faustrup H, Me-lander F, Bartek J, Lukas C and Lukas J.
RNF8 ubiquitylates histones at DNA double-
strand breaks and promotes assembly of repair
proteins. Cell 2007; 131: 887�900.56� Kim H, Chen J, Yu X. Ubiquitin-binding pro-tein RAP80 mediates BRCA1-dependent DNA
damage response. Science 2007; 316: 1202�1205.
57� Sobhian B, Shao G, Lilli DR, Culhane AC,Moreau LA, Xia B, Livingston DM and
Greenberg RA. RAP80 targets BRCA1 to spe-
cific ubiquitin structures at DNA damage sites.
Science 2007; 316: 1198�1202.58� Wang B, Matsuoka S, Ballif BA, Zhang D,Smogorzewska A, Gygi SP and Elledge SJ.
Abraxas and RAP80 form a BRCA1 protein
complex required for the DNA damage re-
sponse. Science 2007; 316: 1194�1198.59� Hashizume R, Fukuda M, Maeda I, Nishi-kawa H, Oyake D, Yabuki Y, Ogata H and
Ohta T. The RING heterodimer BRCA1-
BARD1 is a ubiquitin ligase inactivated by a
breast cancer-derived mutation. J Biol Chem
2001; 276: 14537�14540.60� Nishikawa H, Ooka S, Sato K, Arima K, Oka-
����������� ������ 81
81
moto J, Klevit RE, Fukuda M and Ohta T.
Mass spectrometric and mutational analyses
reveal Lys-6-linked polyubiquitin chains cata-
lyzed by BRCA1-BARD1 ubiquitin ligase. J
Biol Chem 2004; 279: 3916�3924.61� Brzovic PS, Kee#e JR, Nishikawa H, Miya-
moto K, Fox D, 3rd, Fukuda M, Ohta T and
Klevit R. Binding and recognition in the as-
sembly of an active BRCA1�BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci USA 2003;
100: 5646-5651.
62� Wu-Baer F, Lagrazon K, Yuan W and Baer R.
The BRCA1 �BARD1 heterodimer assemblespolyubiquitin chains through an unconven-
tional linkage involving lysine residue K6 of
ubiquitin. J Biol Chem 2003; 278: 34743�34746.
63� Sato K, Hayami R, Wu W, Nishikawa T,Nishikawa H, Okuda Y, Ogata H, Fukuda M
and Ohta T. Nucleophosmin�B23 is a candi-date substrate for the BRCA1-BARD1 ubiq-
uitin ligase. J Biol Chem 2004; 279: 30919�30922.
���� ����82
82